Clinical trial
Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)
NCT07444203 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)
- Lead sponsor
- University of Pennsylvania
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 12, 2025
- Completion date
- November 12, 2028
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.